Concentra Group Holdings Parent, Inc. (CON) is a publicly traded company in the Healthcare — Medical - Care Facilities industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Concentra Group Holdings Parent, Inc. is a U.S.-based provider of occupational health solutions. The company delivers a comprehensive suite of occupational and consumer health services, encompassing treatment for workers' compensation injuries, urgent care, diagnostic clinical testing, preventative health measures, and employer-specific programs, along with wellness initiatives.
Is Concentra Group Holdings Parent, Inc. stock overvalued or undervalued in 2026?
Concentra Group Holdings Parent, Inc. (CON) trades at 26.4× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $47 (+15 %).
Kaplio overview: Concentra Group Holdings Parent, Inc.
Market cap $5B · 52 weeks $19 – $41 (0 % below the high) · P/E 26.4× · 2027 expected P/E 22.0× · Dividend 0.62 % · Next earnings November 5, 2026 · expected EPS $0.44 · Closing price, Oct 28 · accounts published Aug 6.
- Valuation: P/E 26.4× (fairly priced).
- Business: ROIC 11 % (fair).
- Balance sheet: Net debt/EBITDA 4.9× (fragile).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
At its sector median (30.4×) $47 (+15 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 1 of 6 pass
- R&D / Revenue 0.0 %, fails.
- Gross margin 28.3 %, fails.
- ROIC 10.5 %, fails.
- Net debt / EBITDA 4.9×, fails.
- P/E vs own 10y history 26.4×, fails.
- FCF / Net Income 118.4 %, passes.
Against its peers (reference peers) — Concentra Group Holdings Parent, Inc.: P/E 26.4×; EV/EBITDA 15.4×; ROIC 10.5 %; $5.2B. Addus HomeCare Corporation (P/E 21.4×; EV/EBITDA 13.6×; ROIC 8.5 %; $2.3B), Haemonetics Corporation (P/E 58.0×; EV/EBITDA 24.5×; ROIC 8.6 %; $5.4B), Integer Holdings Corporation (P/E 34.6×; EV/EBITDA 18.0×; ROIC 5.1 %; $4.3B).
Dividend
tight · Yield 0.62 % ($0.25 per share in 2025) · paying since 2023 · Free cash flow coverage 0.4× · With $1,000 invested today you'd collect $6.20 a year ($0.52 a month).
Profitability
| Return on Equity | 47.30% |
| Return on Invested Capital | 10.51% |
| Return on Assets | 6.60% |
| Gross Margin | 29.31% |
| Operating Margin | 16.39% |
| Net Margin | 8.69% |
Financial Health
| Debt / Equity | 4.49 |
| Current Ratio | 1.38 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.73 |
Price Performance
| 1 month | +14.86% |
| 3 months | +28.25% |
| Year-to-date | +106.25% |
| 1 year | +101.84% |
Dividend History
Paid in the last 12 months: $0.2500 per share in 4 payments.
| Date | Amount |
|---|---|
| 2026-08-20 | $0.0625 |
| 2026-05-19 | $0.0625 |
| 2026-03-12 | $0.0625 |
| 2025-12-02 | $0.0625 |
| 2025-08-21 | $0.0625 |
| 2025-05-20 | $0.0625 |
| 2025-03-18 | $0.0625 |
| 2024-11-13 | $0.0625 |
Amounts adjusted for stock splits.
Related companies: BEAM · HCM · ADUS · ITGR · PBH · HAE · BHC
Explore sector: Healthcare · Medical - Care Facilities
More sections of CON: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks